Effect of pxdn on pulmonary hypertension mediated by apoptosis of smooth muscle cells

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035802

Enrollment

Unknown

Registered

2020-08-17

Start date

2020-08-17

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary hypertension

Interventions

Pulmonary hypertension group:N/A

Control group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Pulmonary hypertension group: Patients with pulmonary hypertension confirmed by right heart catheterization. Control group: matched with age, gender and BMI of pulmonary hypertension group, patients with low probability of pulmonary hypertension or right heart catheterization did not meet the diagnostic criteria of pulmonary hypertension by echocardiography.

Exclusion criteria

Exclusion criteria: 1. Patients with heart failure caused by myocarditis and / or pericarditis; 2. Patients with acute and chronic bacterial and / or viral infections; 3. Patients with acute myocardial ischemia; 4. Patients with severe liver / renal insufficiency (ALT > 3 ULN, EGFR < 30 ml / min); 5. Patients with diabetes, hyperthyroidism and severe anemia (HB < 60 g / L); 6. Malignant tumor, pregnancy.

Design outcomes

Primary

Measure	Time frame
PXDN;cell pyroptosis;	—

Countries

China

Contacts

Public ContactRuizheng Shi

Xiangya Hospital Central South University

188112168@csu.edu.cn+86 15953167761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026